|
Patient
|
Diagnosis
|
Medication
|
Pre-injection VA
|
VA at presentation
|
Days to presentation
|
Treatment
|
Culture results
|
Continued anti-VEGF?
|
Final VA
|
Length of follow-up (months)
|
|---|
|
1
|
BRVO/CME
|
Bevacizumab
|
20/50
|
CF
|
2
|
Tap/inject
|
CONS
|
N
|
20/40 − 1
|
12
|
|
2
|
BRVO/CME
|
Bevacizumab
|
20/100
|
HM
|
3
|
Tap/inject, then PPV
|
CONS
|
Y
|
20/125
|
23
|
|
3
|
CRVO/CME
|
Bevacizumab
|
20/40
|
CF
|
15
|
PPV
|
CONS
|
N
|
HM
|
26
|
|
4
|
DME
|
Bevacizumab
|
20/60
|
CF
|
4
|
Tap/inject
|
CONS
|
Y
|
20/80
|
22
|
|
5
|
NVAMD
|
Bevacizumab
|
20/40 − 2
|
20/80
|
3
|
Tap/inject
|
CONS
|
Y
|
20/80
|
25
|
|
6
|
Radiation retinopathy s/p plaque therapy for MM
|
Ranibizumab
|
20/200
|
HM
|
3
|
Tap/inject
|
CONS
|
Y
|
20/250
|
11
|
|
7
|
NVAMD
|
Ranibizumab
|
20/100
|
CF
|
7
|
Tap/inject, then PPV
|
CONS
|
N
|
20/160, ph 20/125
|
13
|
|
8
|
DME
|
Bevacizumab
|
? (elsewhere)
|
HM
|
4
|
Tap/inject, then PPV
|
CONS
|
Y
|
20/40
|
10
|
|
9
|
CRVO/CME
|
Ranibizumab
|
20/63
|
CF
|
3
|
Tap/inject
|
Corynebacterium
|
Y
|
20/80
|
23
|
|
10
|
MC/CNV
|
Ranibizumab
|
20/25
|
HM
|
1
|
Tap/inject, then PPV
|
Strep viridans, Neisseria
|
Y
|
20/160
|
16
|
|
11
|
NVAMD
|
Bevacizumab
|
? (elsewhere)
|
20/400
|
4
|
Tap/inject, then PPV
|
E. coli, Enterobacter cloacae
|
N
|
20/50 + 2
|
4
|
|
12
|
NVAMD
|
Bevacizumab
|
20/126
|
20/100
|
4
|
Tap/inject, then PPV
|
Lactococcus garvieae, CONS
|
Y
|
20/40
|
18
|
|
13
|
NVAMD
|
Bevacizumab
|
20/80
|
CF
|
5
|
Tap/inject
|
No growth
|
Y
|
20/150
|
22
|
|
14
|
CRVO/CME
|
Bevacizumab
|
20/250 − 3
|
HM
|
4
|
Tap/inject
|
No growth
|
N
|
HM
|
4
|
|
15
|
NVAMD
|
Ranibizumab
|
20/200 − 2
|
1/200
|
4
|
Tap/inject
|
No growth
|
N
|
CF
|
21
|
|
16
|
CRVO/CME
|
Ranibizumab
|
?
|
20/100
|
3
|
Tap/inject
|
No growth
|
Y
|
?
|
1
|
- Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent
-
Abbreviations: VA visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, DME diabetic macular edema, NVAMD neovascular age-related macular degeneration, MC multifocal choroiditis, CNV choroidal neovascularization, MM malignant choroidal melanoma, CF counting fingers, HM hand motions, PPV pars plana vitrectomy, CONS coagulase-negative Staphylococcus
